<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01304043</url>
  </required_header>
  <id_info>
    <org_study_id>TMRO</org_study_id>
    <nct_id>NCT01304043</nct_id>
  </id_info>
  <brief_title>French Observatory of Rare Malignant Tumors of the Ovary</brief_title>
  <official_title>Observatoire Francophone Des Tumeurs Malignes Rares de l'Ovaire : Protocole de Prise en Charge Chez l'Adulte (Tumeurs Germinales et Des Cordons Sexuels)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ARCAGY/ GINECO GROUP</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ARCAGY/ GINECO GROUP</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To take charge of the treatment in rare adult ovarian tumors with an homogenous manner
      (germinal and sexual cords tumors), at different stages of the disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  to establish prognosis factors for the disease

        -  to proceed in a centralised examination of histologic laminas

        -  to reach in the long-term and homogenous follow-up of the patients

        -  to follow-up the long-term toxicities of the treatments given

        -  to analyse and follow-up the later fertility of the patients

        -  to evaluate the interest of setting a multi-disciplinary discussion forum on the Web
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">204</enrollment>
  <condition>Ovarian Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapies protocols</intervention_name>
    <description>Cisplatine 20 mg/m² IV Etoposide 100 mg/m² IV Bléomycine 30 mg IV</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        female with rare ovarian cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 18 years old

          -  germinal or sexual cords ovary tumors histologically proven

          -  first line or relapse treatment

          -  written informed consent

        Exclusion Criteria:

          -  mental ineptitude to understand and follow the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabelle Ray-Coquard, Physician</last_name>
    <role>Principal Investigator</role>
    <affiliation>GINECO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oncologie, Hôtel-Dieu, 1 place du parvis Notre-Dame</name>
      <address>
        <city>Paris</city>
        <zip>75004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.ovaire-rare.org</url>
    <description>information for patients, discussion forum about &quot;difficult&quot; cases, therapeutic strategy for patients presenting rare ovarian tumor</description>
  </link>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>February 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2011</study_first_posted>
  <last_update_submitted>April 19, 2012</last_update_submitted>
  <last_update_submitted_qc>April 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ovarian tumors</keyword>
  <keyword>rare ovarian tumors</keyword>
  <keyword>germinal tumors</keyword>
  <keyword>sexual cords tumors</keyword>
  <keyword>observatory</keyword>
  <keyword>forum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

